Check-Cap Ltd. (NASDAQ:CHEK) Short Interest Up 5.8% in July

Check-Cap Ltd. (NASDAQ:CHEKGet Rating) saw a large increase in short interest in July. As of July 31st, there was short interest totalling 1,100,000 shares, an increase of 5.8% from the July 15th total of 1,040,000 shares. Based on an average trading volume of 470,100 shares, the days-to-cover ratio is presently 2.3 days.

Check-Cap Stock Down 0.4 %

Shares of Check-Cap stock traded down $0.00 during trading hours on Wednesday, reaching $0.36. 4,045 shares of the stock traded hands, compared to its average volume of 416,151. The company has a 50 day moving average price of $0.33 and a 200 day moving average price of $0.39. The firm has a market capitalization of $34.51 million, a price-to-earnings ratio of -1.61 and a beta of 0.43. Check-Cap has a one year low of $0.29 and a one year high of $1.31.

Check-Cap (NASDAQ:CHEKGet Rating) last posted its quarterly earnings results on Wednesday, June 1st. The medical research company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). Sell-side analysts anticipate that Check-Cap will post -0.2 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Check-Cap stock. GSA Capital Partners LLP acquired a new stake in Check-Cap Ltd. (NASDAQ:CHEKGet Rating) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 305,991 shares of the medical research company’s stock, valued at approximately $206,000. GSA Capital Partners LLP owned 0.32% of Check-Cap at the end of the most recent quarter. Institutional investors own 4.87% of the company’s stock.

About Check-Cap

(Get Rating)

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.

Recommended Stories

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.